MindMaze Therapeutics HoldingCHIX:MMTXZ +4.74%15 Gross Margin % is 92.06% as of Dec. 2025, which is at its 10-year median of 92.06. GuruFocus rates CHIX:MMTXZ with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 733 Biotechnology companies, MindMaze Therapeutics Holding ranks better than 87.04% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
MindMaze Therapeutics Holding had a gross margin of 92.06% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
MindMaze Therapeutics Holding Gross Margin % Related Terms
MindMaze Therapeutics Holding Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:MMTXZ vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, MindMaze Therapeutics Holding's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindMaze Therapeutics Holding Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's Gross Margin % distribution charts can be found below:
* The bar in red indicates where MindMaze Therapeutics Holding's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a Gross Margin % of 92.06% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on MindMaze Therapeutics Holding and its competitors. This is near median its historical median of 92.06. Over the past decade, MindMaze Therapeutics Holding's Gross Margin % has ranged from 92.06 to 92.06. According to the industry distribution chart, MindMaze Therapeutics Holding ranks #95 out of 733 companies in the Biotechnology industry, placing it in the top 13%.
Is MindMaze Therapeutics Holding's Gross Margin % too high?
MindMaze Therapeutics Holding's current Gross Margin % of 92.06% is near median its 10-year median of 92.06. Over the past 10 years, this metric has ranged from a low of 92.06 to a high of 92.06. The Biotechnology industry median Gross Margin % is 60.90. MindMaze Therapeutics Holding's value of 92.06% is 51.2% above this industry median. Based on the distribution chart, MindMaze Therapeutics Holding ranks #95 out of 733 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MindMaze Therapeutics Holding has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindMaze Therapeutics Holding ranks #95 out of 733 companies for Gross Margin %. This places MindMaze Therapeutics Holding in the top 13% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.90. MindMaze Therapeutics Holding's value of 92.06% is 51.2% above this benchmark. Historically, MindMaze Therapeutics Holding's own Gross Margin % has ranged from 92.06 to 92.06 over the past decade. While the company's 10-year median is 92.06 vs. the industry median of 60.90, MindMaze Therapeutics Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MindMaze Therapeutics Holding's current Gross Margin % of 92.06% is 51.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on MindMaze Therapeutics Holding and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindMaze Therapeutics Holding's current Gross Margin % is 92.06%, which is near median its own 10-year median of 92.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a current Gross Margin % of 92.06%. The current Gross Margin % is 92.06%, which is near median its 10-year median of 92.06 and 51.2% above the Biotechnology industry median of 60.90. MindMaze Therapeutics Holding's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For MindMaze Therapeutics Holding (CHIX:MMTXZ), the current Gross Margin % is 92.06% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding Business Description
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
15GF Score
Get the complete analysis for CHIX:MMTXZ
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:MMTXZ has been successfully added to your 